SCHEMBL4465203

SCHEMBL4465203

CC(=O)Nc1[nH]cc(-c2ccc(NC(=O)Nc3ccc(C)c(C)c3)cc2)c1C(N)=O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 6/20 0.47
LCK P06239 3/20 0.47
BLK P51451 3/20 0.47
ROCK2 O75116 2/20 0.47
MAP4K4 O95819 2/20 0.47
RET P07949 2/20 0.47
RPS6KB1 P23443 2/20 0.47
GSK3B P49841 2/20 0.47
PRKCD Q05655 2/20 0.47
PRKAA1 Q13131 2/20 0.47
STK3 Q13188 2/20 0.47
ROCK1 Q13464 2/20 0.47
TAOK1 Q7L7X3 2/20 0.47
HIPK4 Q8NE63 2/20 0.47
HIPK2 Q9H2X6 2/20 0.47
MKNK2 Q9HBH9 2/20 0.47
CDK19 Q9BWU1 2/20 0.47
PIM1 P11309 1/20 0.47
NTRK3 Q16288 1/20 0.47
AURKB Q96GD4 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4482796 0.88 KDR (0.53) KDRALDH1A1CSF1RFLT1KIT
SCHEMBL4472475 0.87 CDK8 (0.44) KDRLCKBLKRETMKNK2
SCHEMBL4491792 0.87 MEN1 (0.57) KDRLCKBLKROCK2RPS6KB1
SCHEMBL4481741 0.87 KDR (0.48) KDRLCKBLKROCK2MAP4K4
SCHEMBL4473087 0.87 FLT3 (0.58) KDRLCKBLKROCK2MAP4K4
SCHEMBL4490967 0.86 NPC1 (0.54) KDRLCKBLKROCK2RPS6KB1
SCHEMBL4472148 0.85 IDO1 (0.46) KDRALDH1A1KITSTING1PDGFRB
SCHEMBL4484193 0.84 KMT2A (0.50) KDRALDH1A1KITFLT3POLB
SCHEMBL4480257 0.84 KDR (0.50) KDRLCKBLKROCK2MAP4K4
SCHEMBL4481618 0.84 ROCK2 (0.51) KDRLCKBLKROCK2MAP4K4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7592365-B2 Substituted pyrroles, compositions containing same, method for making same and use thereof AVENTIS PHARMA S.A. (FR) 2009-09-22 US claimed
EP-1851198-B1 SUBSTITUTED PYRROLES, COMPOSITIONS CONTAINING SAME, METHOD FOR MAKING SAME AND USE THEREOF AVENTIS PHARMA SA (FR) 2008-12-31 EP claimed
US-20080167368-A1 Substituted Pyrroles, Compositions Containing Same, Method for Making Same and Use Thereof AVENTIS PHARMA S.A. (FR) 2008-07-10 US claimed
EP-1851198-A1 SUBSTITUTED PYRROLES, COMPOSITIONS CONTAINING SAME, METHOD FOR MAKING SAME AND USE THEREOF Aventis Pharma S.A. (FR) 2007-11-07 EP claimed
WO-2006084996-A1 SUBSTITUTED PYRROLES, COMPOSITIONS CONTAINING SAME, METHOD FOR MAKING SAME AND USE THEREOF AVENTIS PHARMA S.A. (FR) 2006-08-17 WO claimed
US-7592365-B2 Substituted pyrroles, compositions containing same, method for making same and use thereof AVENTIS PHARMA S.A. (FR) 2009-09-22 US disclosed
US-7592365-B2 Substituted pyrroles, compositions containing same, method for making same and use thereof AVENTIS PHARMA S.A. (FR) 2009-09-22 US disclosed
US-7592365-B2 Substituted pyrroles, compositions containing same, method for making same and use thereof AVENTIS PHARMA S.A. (FR) 2009-09-22 US disclosed
EP-1851198-B1 SUBSTITUTED PYRROLES, COMPOSITIONS CONTAINING SAME, METHOD FOR MAKING SAME AND USE THEREOF AVENTIS PHARMA SA (FR) 2008-12-31 EP disclosed
EP-1851198-B1 SUBSTITUTED PYRROLES, COMPOSITIONS CONTAINING SAME, METHOD FOR MAKING SAME AND USE THEREOF AVENTIS PHARMA SA (FR) 2008-12-31 EP disclosed
US-20080167368-A1 Substituted Pyrroles, Compositions Containing Same, Method for Making Same and Use Thereof AVENTIS PHARMA S.A. (FR) 2008-07-10 US disclosed
US-20080167368-A1 Substituted Pyrroles, Compositions Containing Same, Method for Making Same and Use Thereof AVENTIS PHARMA S.A. (FR) 2008-07-10 US disclosed
US-20080167368-A1 Substituted Pyrroles, Compositions Containing Same, Method for Making Same and Use Thereof AVENTIS PHARMA S.A. (FR) 2008-07-10 US disclosed
EP-1851198-A1 SUBSTITUTED PYRROLES, COMPOSITIONS CONTAINING SAME, METHOD FOR MAKING SAME AND USE THEREOF Aventis Pharma S.A. (FR) 2007-11-07 EP disclosed
WO-2006084996-A1 SUBSTITUTED PYRROLES, COMPOSITIONS CONTAINING SAME, METHOD FOR MAKING SAME AND USE THEREOF AVENTIS PHARMA S.A. (FR) 2006-08-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080167368-A1 Substituted Pyrroles, Compositions Containing Same, Method for Making Same and Use Thereof PRMT1, ADPRS, RRM2B KDR 2379/4885LCK 455/4885BLK 3443/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.